New guidelines for managing blood cancers in pregnancy
A new set of guidelines has been developed to assist with the diagnosis and expert management of serious blood cancers in pregnancy. About 12.5 pregnancies per 100,000 are… read more.
A new set of guidelines has been developed to assist with the diagnosis and expert management of serious blood cancers in pregnancy. About 12.5 pregnancies per 100,000 are… read more.
Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb K.K. announced that Ono has received a supplemental approval of Opdivo (generic name: nivolumab) Intravenous Infusion (“Opdivo”), an anti-PD-1 antibody, in… read more.
Checkpoint Therapeutics, Inc. announced that the FDA has approved Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who… read more.
Roche announced that new and updated data from its industry-leading CD20xCD3 T-cell-engaging bispecific antibody programme were presented at the 66th American Society of Hematology (ASH) Annual Meeting &… read more.
Merck Inc., ( known as MSD outside of the United States and Canada), announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted… read more.
Novartis announced results from an updated analysis of the pivotal Phase III NATALEE trial of Kisqal (ribociclib) that underscore the extended efficacy beyond the duration of treatment in… read more.
A meta-analysis of data from 14 studies suggests that consumption of coffee and tea is linked to a reduced risk of head and neck cancer, including cancers of… read more.
NICE (UK) 1.1 Elranatamab is recommended with managed access as an option for treating relapsed and refractory multiple myeloma in adults, only after 3 or more lines of… read more.
GSK plc announced statistically significant and clinically meaningful overall survival (OS) results from a planned interim analysis of the DREAMM-7 trial evaluating Blenrep (belantamab mafodotin) in combination with… read more.
Roche announced data from a 5-year follow-up of the pivotal phase III POLARIX study. Data were presented in an oral session at the 66th American Society of Hematology… read more.
Researchers report that a diet low in omega-6 and high in omega-3 fatty acids, combined with fish oil supplements has led to a reduced growth rate of prostate… read more.
Novartis announced positive, longer-term results from the pivotal Phase III ASC4FIRST trial with Scemblix (asciminib) showing superior major molecular response (MMR) rates at week 96 . The study… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.